1.Efficacy and Safety of Weekly Alendronate Plus Vitamin D3 5600 IU versus Weekly Alendronate Alone in Korean Osteoporotic Women: 16-Week Randomized Trial.
Kwang Joon KIM ; Yong Ki MIN ; Jung Min KOH ; Yoon Sok CHUNG ; Kyoung Min KIM ; Dong Won BYUN ; In Joo KIM ; Mikyung KIM ; Sung Soo KIM ; Kyung Wan MIN ; Ki Ok HAN ; Hyoung Moo PARK ; Chan Soo SHIN ; Sung Hee CHOI ; Jong Suk PARK ; Dong Jin CHUNG ; Ji Oh MOK ; Hong Sun BAEK ; Seong Hwan MOON ; Yong Soo KIM ; Sung Kil LIM
Yonsei Medical Journal 2014;55(3):715-724
Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients have low levels of 25-hydroxy-vit-D [25(OH)D]. This randomized, open-label study compared the effects of once weekly alendronate 70 mg containing 5600 IU vit-D3 (ALN/D5600) to alendronate 70 mg without additional vit-D (ALN) on the percent of patients with vit-D insufficiency [25(OH)D <15 ng/mL, primary endpoint] and serum parathyroid hormone (PTH, secondary endpoint) levels in postmenopausal, osteoporotic Korean women. Neuromuscular function was also measured. A total of 268 subjects were randomized. Overall, 35% of patients had vit-D insufficiency at baseline. After 16-weeks, there were fewer patients with vit-D insufficiency in the ALN/D5600 group (1.47%) than in the ALN group (41.67%) (p<0.001). Patients receiving ALN/D5600 compared with ALN were at a significantly decreased risk of vit-D insufficiency [odds ratio=0.02, 95% confidence interval (CI) 0.00-0.08]. In the ALN/D5600 group, significant increases in serum 25(OH)D were observed at weeks 8 (9.60 ng/mL) and 16 (11.41 ng/mL), where as a significant decrease was recorded in the ALN group at week 16 (-1.61 ng/mL). By multiple regression analysis, major determinants of increases in serum 25(OH)D were ALN/D5600 administration, seasonal variation, and baseline 25(OH)D. The least squares mean percent change from baseline in serum PTH in the ALN/D5600 group (8.17%) was lower than that in the ALN group (29.98%) (p=0.0091). There was no significant difference between treatment groups in neuromuscular function. Overall safety was similar between groups. In conclusion, the administration of 5600 IU vit-D in the ALN/D5600 group improved vit-D status and reduced the magnitude of PTH increase without significant side-effects after 16 weeks in Korean osteoporotic patients.
Adult
;
Aged
;
Alendronate/adverse effects/*therapeutic use
;
Cholecalciferol/adverse effects/deficiency/*therapeutic use
;
Female
;
Humans
;
Middle Aged
;
Osteoporosis, Postmenopausal/*drug therapy
;
Vitamin D Deficiency/*drug therapy
2.Effect of alendronate on glucocorticoid-induced osteoporosis.
Xiaoling ZOU ; Qinxue LI ; Chunhua SHI
Journal of Central South University(Medical Sciences) 2009;34(6):563-565
OBJECTIVE:
To determine the effect of alendronate on glucocorticoid-induced osteoporosis(GIO).
METHODS:
Thirty-five GIO patients were enrolled. Ten milligrams alendronate were prescribed daily for 6 months. Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometer (DEXA) after and before the treatment.
RESULTS:
BMD at lumbar, neck and trochanter sites of the 35 patients after the treatment was significantly increased compared with those before the treatment (P<0.05). Urine Ca/Cr level was decreased (P<0.05). There was no severe side effect.
CONCLUSION
Alendronate is effective and well tolerated for GIO.
Adult
;
Alendronate
;
therapeutic use
;
Bone Density
;
drug effects
;
Bone Density Conservation Agents
;
therapeutic use
;
Female
;
Humans
;
Male
;
Middle Aged
;
Osteoporosis
;
chemically induced
;
drug therapy
;
Prednisone
;
adverse effects
;
therapeutic use
;
Rheumatic Fever
;
drug therapy
3.Comparison of Effect of Treatment with Etidronate and Alendronate on Lumbar Bone Mineral Density in Elderly Women with Osteoporosis.
Jun IWAMOTO ; Tsuyoshi TAKEDA ; Yoshihiro SATO ; Mitsuyoshi UZAWA
Yonsei Medical Journal 2005;46(6):750-758
The purpose of this open-labeled prospective study was to compare the treatment effects of cyclical etidronate and alendronate on the lumbar bone mineral density (BMD), bone resorption, and back pain in elderly women with osteoporosis. Fifty postmenopausal women with osteoporosis, age ranging from 55 to 86 years (mean: 70.7 years), were randomly divided into two groups with 25 patients in each group: the cyclical etidronate group (etidronate 200 mg daily for 2 weeks every 3 months) and the alendronate group (5 mg daily). The BMD of the lumbar spine (L1-L4) measured by DXA, the urinary cross-linked N-terminal telopeptides of type I collagen (NTX) level measured by the enzyme-linked immunosorbent assay, and back pain evaluated by the face scale score were assessed at baseline, 6 months, and 12 months. There were no significant differences in baseline characteristics including age, body mass index, years since menopause, lumbar BMD, urinary NTX level, and face scale score between the two treatment groups. Etidronate treatment sustained the lumbar BMD following a reduction in the urinary NTX level and improved back pain, while alendronate treatment reduced the urinary NTX level more significantly, resulting in an increase in the lumbar BMD, and similarly improved back pain. No serious adverse events were observed in either group. This study confirmed that alendronate treatment had a greater efficacy than etidronate treatment in increasing the lumbar BMD through the reduction of bone resorption in elderly women with osteoporosis.
Spinal Fractures/prevention & control/radiography
;
Osteoporosis, Postmenopausal/*drug therapy
;
Middle Aged
;
Lumbar Vertebrae/*drug effects
;
Humans
;
Female
;
Etidronic Acid/adverse effects/*therapeutic use
;
Bone Density Conservation Agents/adverse effects/*therapeutic use
;
Bone Density/*drug effects
;
Biological Markers/blood/urine
;
Back Pain/drug therapy
;
Alendronate/adverse effects/*therapeutic use
;
Aged, 80 and over
;
Aged
4.Comparison of Effects of Alendronate and Raloxifene on Lumbar Bone Mineral Density, Bone Turnover, and Lipid Metabolism in Elderly Women with Osteoporosis.
Jun IWAMOTO ; Yoshihiro SATO ; Mitsuyoshi UZAWA ; Tsuyoshi TAKEDA ; Hideo MATSUMOTO
Yonsei Medical Journal 2008;49(1):119-128
PURPOSE: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis. Subjects and Methods: One hundred twenty-two postmenopausal women with osteoporosis (mean age: 69.4 years) were randomly divided into 2 groups of 61 patients: the alendronate group and the raloxifene group. BMD of the lumbar spine, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP), total cholesterol (TC), high and low density lipoprotein cholesterols (LDL-C and HDL-C, respectively), and triglycerides (TG) were measured during the 12-month-treatment period. RESULTS: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both alendronate and raloxifene increased lumbar BMD (+8.0% and +2.4% at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9% and -7.7% at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. CONCLUSION: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BMD through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.
Aged
;
Alendronate/adverse effects/pharmacology/*therapeutic use
;
Biological Markers/blood
;
Bone Density/*drug effects
;
Calcium/blood
;
Female
;
Fractures, Bone/prevention & control
;
Humans
;
Lipid Metabolism/*drug effects
;
Osteoporosis/*drug therapy/*metabolism
;
Phosphorus/blood
;
Raloxifene/adverse effects/pharmacology/*therapeutic use
;
Spine/drug effects